CyanVac has received US federal funding through the Project NextGen initiative to conduct a Phase IIb comparative clinical trial of its intranasal parainfluenza virus 5 (PIV5)-based vaccine candidate, CVXGA.
Facilitated by the US Department of Health and Human Services, the funding aims to advance innovative vaccines offering broader protection against Covid-19.
Go deeper with GlobalData
To be executed through the clinical studies network of the Biomedical Advanced Research and Development Authority (BARDA), the upcoming trial involving 10,000 participants will be sponsored by CyanVac.
The double-blinded, randomised trial will compare CVXGA’s efficacy, safety, and immunogenicity against an mRNA-based Covid-19 vaccine approved by the US Food and Drug Administration (FDA).
Anticipated to begin later this year, the trial will focus on individuals at a higher risk of severe illness, assessing the vaccine’s ability to prevent both severe and asymptomatic Covid-19 infections.
CyanVac and its affiliate Blue Lake Biotechnology are developing the single-dose, intranasal vaccine to protect against SARS-CoV-2 infection and its severe outcomes.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIn preclinical studies, CVXGA was found to be immunogenic, protective, and could prevent virus transmission.
Phase I trials have demonstrated that subjects receiving CVXGA exhibited strong mucosal, cellular, and humoral immune responses, with minimal reactogenicity and no serious vaccine-related events.
CyanVac founder and CEO Biao He said: “This award will accelerate the development of our PIV5-based intranasal Covid-19 vaccine, building on our very promising Phase I and preliminary Phase IIa clinical trial results.
“PIV5 is a novel intranasal vaccine vector that has been shown to replicate safely in humans in clinical trials and stimulates all three pillars of immunity, cellular, mucosal, and humoral – with minimal uncomfortable side effects.
“The successful development of an intranasal Covid-19 vaccine using this new vector will demonstrate the capabilities of our PIV5 platform and benefit the development of PIV5-based vaccines for other emerging infectious diseases.”
